PTGX
Protagonist Therapeutics, Inc
NASDAQ · Healthcare · Biotechnology · US
$134.44
+4.42%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 282.0M | 46.0M | 434.4M | 60.0M | 26.6M |
| Cost of Revenue | 407.0K | 1.2M | — | — | — |
| Gross Profit | 281.6M | 44.8M | 434.4M | 60.0M | 26.6M |
| Operating Expenses | |||||
| R&D Expense | 175.2M | 159.3M | 138.1M | 120.2M | 126.2M |
| SG&A Expense | 48.5M | 44.9M | 43.5M | 33.5M | 31.7M |
| General & Admin Expense | 48.5M | 44.9M | 43.5M | 33.5M | 31.7M |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | (407.0K) | (1.2M) | — | — | — |
| Total Operating Expenses | 223.2M | 202.9M | 181.6M | 153.7M | 158.0M |
| Cost and Expenses | 223.7M | 204.1M | 181.6M | 153.7M | 158.0M |
| Operating Income (EBIT) | 58.3M | (158.1M) | 252.8M | (93.7M) | (131.4M) |
| Non-Operating | |||||
| Interest Income | 26.1M | 28.8M | 26.3M | 14.9M | 4.1M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 26.1M | 28.8M | 26.3M | 14.9M | 4.1M |
| Other Non-Op Income/Expense | 26.0M | 28.8M | 26.6M | 14.7M | 4.0M |
| Non-Operating Income (excl Interest) | (26.0M) | (28.8M) | (26.6M) | (14.7M) | (4.0M) |
| EBT (Pre-Tax Income) | 84.3M | (129.3M) | 279.4M | (79.0M) | (127.4M) |
| Income Tax Expense | 1.4M | 838.0K | 4.2M | — | — |
| Bottom Line | |||||
| Net Income | 82.9M | (130.1M) | 275.2M | (79.0M) | (127.4M) |
| Earnings from Cont. Ops | 82.9M | (130.1M) | 275.2M | (79.0M) | (127.4M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 82.9M | (130.1M) | 275.2M | (79.0M) | (127.4M) |
| Per Share | |||||
| Basic EPS | $1.22 | ($2.05) | $4.47 | ($1.39) | ($2.52) |
| Diluted EPS | $1.03 | ($2.05) | $4.23 | ($1.39) | ($2.52) |
| Revenue Per Share | $4.28 | $0.72 | $7.06 | $1.06 | $0.54 |
| Shares | |||||
| Basic Shares Outstanding | 65.9M | 63.6M | 61.6M | 56.8M | 49.0M |
| Diluted Shares Outstanding | 71.0M | 63.6M | 65.1M | 56.8M | 49.0M |
| Profitability Metrics | |||||
| EBITDA | 85.9M | (128.0M) | 282.4M | (75.6M) | (124.0M) |
| D&A | 1.5M | 1.3M | 3.0M | 3.3M | 3.4M |
| EBIT | 84.3M | (129.3M) | 279.4M | (79.0M) | (127.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026